stockportfolio.pro
Stocks / MDGL vs TECH
MDGL vs TECH: Which Stock Is the Better Buy?
Madrigal Pharmaceuticals, Inc. and Bio-Techne Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
TECH is the larger company ($11.0B vs $11.0B). On the fundamentals, TECH earns a higher net margin (6.0% vs -30.1%); TECH has the stronger return on equity (3.8% vs -47.8%). On the filings, TECH carries fewer potential red flags (1 vs 3). Full numbers below — the stronger figure on each row is in green.
AI verdict — MDGL vs TECH, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Madrigal Pharmaceuticals, Inc. (MDGL) | Bio-Techne Corporation (TECH) | |
|---|---|---|
| Market cap | $11.0B | $11.0B |
| Revenue (latest FY) | $958.40M | $1.22B |
| Net income (latest FY) | $-288.28M | $73.40M |
| Revenue growth (5y CAGR) | — | 10.5% |
| Net margin | -30.1% | 6.0% |
| Return on equity | -47.8% | 3.8% |
| P/E ratio | — | 101.2 |
| Dividend yield | — | 0.4% |
| Profitable years (of last 10) | 0 | 10 |
| Positive free cash flow | No | Yes |
Compare with another company:
See the full MDGL vs TECH breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open MDGL's full financials → Open TECH's full financials →More comparisons
Frequently asked questions
Which is bigger, MDGL or TECH?
Bio-Techne Corporation is larger by market capitalization — $11.0B versus $11.0B.
Which grows faster, MDGL or TECH?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.